By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Immune globulins > Rhophylac > Rhophylac Dosage
Immune globulins
https://themeditary.com/dosage-information/rhophylac-dosage-3931.html

Rhophylac Dosage

Drug Detail:Rhophylac (Rho (d) immune globulin [ roe-d-im-myoon-glob-yoo-lin ])

Generic Name: HUMAN RHO(D) IMMUNE GLOBULIN 1500[iU] in 2mL

Dosage Form: injection

Drug Class: Immune globulins

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Observe patients for at least 20 minutes following administration of RHOPHYLAC.

Preparation and Handling

  • RHOPHYLAC is a clear or slightly opalescent, colorless to pale yellow solution. Inspect RHOPHYLAC visually for particulate matter and discoloration prior to administration. Do not use if the solution is cloudy or contains particulates.
  • Prior to intravenous use, ensure that the needle-free intravenous administration system is compatible with the tip of the RHOPHYLAC glass syringe.
  • Do not freeze.
  • Bring RHOPHYLAC to room temperature before use.
  • RHOPHYLAC is for single dose only. Dispose of any unused product or waste material in accordance with local requirements.

Administration

​DO NOT confuse micrograms (mcg) with International Units (IU) when calculating the dose of RHOPHYLAC. Miscalculations could result in a significant overdose or underdose of the product. Note that 1 mcg = 5 IU of RHOPHYLAC.

Suppression of Rh Isoimmunization

RHOPHYLAC should be administered by intravenous or intramuscular injection. If large doses (greater than 5 mL) are required and intramuscular injection is chosen, it is advisable to administer RHOPHYLAC in divided doses at different sites.

Ensure the site of administration will allow the injection to reach the muscle if RHOPHYLAC is administered intramuscularly. Consider intravenous administration if reaching the muscle is of concern [see Adverse Reactions (6.2)]. Do not administer RHOPHYLAC subcutaneously into the fatty tissue.

Refer to Table 1 (for dosing instructions in micrograms) and Table 2 (for dosing instructions in International Units) by indication.

Table 1. Dosing Guidelines based on Micrograms (mcg) for Suppression of Rh Isoimmunization
​MICROGRAMS (mcg)
​Indication Timing of Administration Dose*
(Administer by intravenous (IV) or intramuscular (IM) injection)
*
A 300 mcg dose of RHOPHYLAC will suppress the immunizing potential of ≤15 mL of fetal Rh(D)-positive RBCs.1
†
The dose of RHOPHYLAC must be increased if the patient is exposed to >15 mL of fetal Rh(D)-positive RBCs; in this case, follow the dosing guidelines for excessive fetomaternal hemorrhage.
​Rh-incompatible pregnancy
​ Routine antepartum prophylaxis Week 28-30 of pregnancy 300 mcg
​ Postpartum prophylaxis (required only if the newborn is Rh(D)-positive, or of unknown status) Within 72 hours of birth 300 mcg†
​ Obstetric complications (e.g., miscarriage, abortion, threatened abortion, ectopic pregnancy or hydatidiform mole, transplacental hemorrhage resulting from antepartum hemorrhage) Within 72 hours of complication 300 mcg†
​ Invasive procedures during pregnancy (e.g., amniocentesis, chorionic biopsy) or obstetric manipulative procedures (e.g., external version, abdominal trauma) Within 72 hours of procedure 300 mcg†
​ Excessive fetomaternal hemorrhage (>15 mL fetal RBCs) Within 72 hours of complication 300 mcg plus:
  • 20 mcg per mL Rh(D)-positive fetal RBCs in excess of 15 mL if excess transplacental bleeding is quantified
    or
  • An additional 300 mcg dose if excess transplacental bleeding cannot be quantified
​Incompatible transfusions Within 72 hours of exposure 20 mcg per 2 mL transfused Rh(D)-positive whole blood or per 1 mL Rh(D)-positive RBCs
Table 2. Dosing Guidelines based on International Units (IU) for Suppression of Rh Isoimmunization
​INTERNATIONAL UNITS (IU)
​Indication Timing of Administration Dose*
(Administer by intravenous (IV) or intramuscular (IM) injection)
*
A 1500 IU dose of RHOPHYLAC will suppress the immunizing potential of ≤15 mL of fetal Rh(D)-positive RBCs.1
†
The dose of RHOPHYLAC must be increased if the patient is exposed to >15 mL of fetal Rh(D)-positive RBCs; in this case, follow the dosing guidelines for excessive fetomaternal hemorrhage.
​Rh-incompatible pregnancy
​ Routine antepartum prophylaxis Week 28-30 of pregnancy 1500 IU
​ Postpartum prophylaxis (required only if the newborn is Rh(D)-positive, or of unknown status) Within 72 hours of birth 1500 IU†
​ Obstetric complications (e.g., miscarriage, abortion, threatened abortion, ectopic pregnancy or hydatidiform mole, transplacental hemorrhage resulting from antepartum hemorrhage) Within 72 hours of complication 1500 IU†
​ Invasive procedures during pregnancy (e.g., amniocentesis, chorionic biopsy) or obstetric manipulative procedures (e.g., external version, abdominal trauma) Within 72 hours of procedure 1500 IU†
​ Excessive fetomaternal hemorrhage (>15 mL fetal RBCs) Within 72 hours of complication 1500 IU plus:
  • 100 IU per mL fetal RBCs in excess of 15 mL if excess transplacental bleeding is quantified
    or
  • An additional 1500 IU dose if excess transplacental bleeding cannot be quantified
​Incompatible transfusions Within 72 hours of exposure 100 IU per 2 mL transfused Rh(D)- positive whole blood or per 1 mL RBCs

Treatment of ITP

For treatment of ITP, ADMINISTER RHOPHYLAC BY THE INTRAVENOUS ROUTE ONLY [see Dosage and Administration (2.1)]. Do not administer intramuscularly.

Calculate the dose of RHOPHYLAC for ITP on the basis of the patient's weight in kilograms (kg). Inappropriate use of pounds (lbs) will result in an overdose.

Table 3. Dosing Guidelines for ITP
Dose (mcg) Rate of administration
mcg = microgram
50 mcg per kg body weight 2 mL per 15 to 60 seconds

The following formula can be used to calculate the number of syringes of RHOPHYLAC to administer:

Dose (50 mcg) x body weight (kg) = Total mcg / 300 mcg per syringe = Number of syringes

Share this Article
Latest News
Medical News

Aging and longevity: What role might coffee play?

Jun 02, 2025
Seed oils: Omega-6 fatty acids may lower diabetes, heart disease risk
Type 2 diabetes: Sugary drinks may significantly raise risk
COVID-19: Who do the new vaccine guideline changes affect?
Vitamin D supplements may help slow down aging by 3 years
Aging: Exercise timing, consistency can affect heart and lung fitness
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by